Wird geladen...
Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
A screen by Kost-Alimova et al.(1) suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
Gespeichert in:
| Veröffentlicht in: | Cell Rep Med |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Elsevier
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7670931/ https://ncbi.nlm.nih.gov/pubmed/33225317 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xcrm.2020.100145 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|